logo-loader
RNS
GenIP PLC

GenIP PLC - New & recurring contract wins

RNS Number : 0499Q
GenIP PLC
11 August 2026
 

 

 

GenIP Plc

("GenIP" or the "Company")

 

New & recurring contract wins

GenIP secures multiple new and recurring contracts for a total consideration of $87k

 

GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, announces a number of new and recurring contract wins across its key markets for a total consideration of $87k.

 

Chile

GenIP has further expanded its relationship with Universidad Autónoma de Chile, a long-standing customer of the Company's Invention Evaluator platform, through the purchase of a further 25 Invention Evaluator reports. The University has also invited GenIP to join its Technical Advisory Committee, reinforcing the Company's position as a trusted commercialisation partner and embedding GenIP within one of Chile's leading innovation ecosystems.

 

Additionally, Gen IP has received a repeat order from an existing university customer for a further 20 Invention Evaluator reports and won a new contract to deliver 15 Invention Evaluator reports for another research university in Chile. This leading research university has a portfolio of approximately 500 technologies, presenting an opportunity for significant future engagement and marks the third customer secured in Chile.

 

United Kingdom

A leading research university in the UK has reengaged GenIP for a further 12 Invention Evaluation reports. This marks the second time GenIP has been commissioned by this University following an initial purchase of 10 reports last year. The continued expansion of this relationship strengthens GenIP's recurring revenue profile, demonstrates the quality of service delivered and supports management's confidence in the long-term UK growth opportunity.

 

North America

GenIP continues to experience strong recurring demand from one of North America's leading research universities, which continues to purchase Invention Evaluator reports on a near bi-weekly basis. The consistent level of repeat business highlights the ongoing value delivered by GenIP's technology and demonstrates the potential for long-term recurring revenue from established institutional clients.

 

Talent Search

GenIP has secured a new Talent Search engagement contract demonstrating the continued diversification of the Company's revenue beyond technology evaluation services. This engagement, together with several additional Talent Search opportunities currently under discussion, reflects the early success of the strategic repositioning of GenIP and supports the Company's strategy of expanding into higher-value, complementary revenue streams.

 

Melissa Cruz, CEO of GenIP, commented:

"I am pleased with the continued momentum across our key markets, with expanding customer relationships in Chile, the UK and North America demonstrating the growing demand for GenIP's technology commercialisation services. 

 

"The strengthening of our relationship with Universidad Autónoma de Chile, alongside new customer wins in the region, highlights the opportunity for further growth in Latin America. At the same time, repeat engagements in the UK and ongoing demand from North America demonstrate the value of our services and the potential for long-term recurring revenue.

 

"I am encouraged by the early success of our Talent Search offering, which is broadening our revenue opportunities, while our continued industry engagement is helping to strengthen GenIP's position as a leader in AI-enabled technology commercialisation.

 

"With a growing international presence and a strong pipeline of opportunities, we remain confident in GenIP's ability to deliver further growth."

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc

Melissa Cruz, CEO

 

Via Walbrook PR

 


Walbrook PR (Financial PR)

Alice Woodings

William Turner

GenIP@walbrookpr.com

Tel: +44 (0)7407 804 654

Tel: +44 (0)7407 020 470

 


focusIR (Investor Relations)

Kat Perez

Dr Paul Cornelius

GenIP@focusIR.com

Tel: +44 (0)20 4570 2234

Tel: +44 (0)20 4570 2246

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

About GenIP

GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

 

Service Offerings

GenIP operates through two synergistic service lines:

 

Service

Description

Value Proposition

Invention Intelligence Product Suite

AI-powered market intelligence reports assessing the commercial potential of emerging technologies

Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy

 

IP Commercialisation Services

 

 

End-to-end engagement to help research organisations commercialise innovations

 

 

Provides cost-effective, broad support to achieve our clients' strategic objectives

 

 

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

 

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

 

·    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

·    Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

·    Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAPPEFLFKEFA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read